CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
single-agent in the setting of Relapsed or refractory acute myeloid leukemia (R/R AML).The dose escalation (Part A) of the study will explor...
Phase 1
Birmingham, Alabama, United States and 13 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Birmingham, Alabama, United States and 13 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Birmingham, Alabama, United States and 110 other locations
phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia...
Phase 1
Birmingham, Alabama, United States
with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who are refractory to or have relapsed after first-line AML therap...
Phase 3
Birmingham, Alabama, United States and 125 other locations
safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 25 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...
Phase 1
Birmingham, Alabama, United States and 32 other locations
of CB-012 (the study treatment) in adults with acute myeloid leukemia (AML) that has come back after prior treatment (relapsed) or did not r...
Phase 1
Birmingham, Alabama, United States and 9 other locations
Clinical trials
Research sites
Resources
Legal